Elizabeth Lihua Budde, M.D., Ph.D.

(877) 460-4673
Elizabeth Lihua Budde, M.D., Ph.D.
Hematologist-Oncologist
Clinical Expertise
  • Lymphoma
  • Leukemia
  • Bone Marrow and Stem Cell Transplant
Research Area
  • Immunotherapies for Leukemia and Lymphoma
Other Languages Spoken
Mandarin
Academic Appointments
  • Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
  • Executive Medical Director, Enterprise Immune Effector Cell Program
Clinical Teams
Acute Myeloid Leukemia
Hematology & Hematopoietic Cell Transplantation
Leukemia
Lymphoma

Elizabeth Budde, M.D., Ph.D. is a distinguished expert in the field of hematology, specializing in treatment and research of blood malignancies. Her scholarly and clinical pursuits are dedicated to developing innovative therapies for patients battling lymphoma and leukemia. In her dual role as a physician scientist, she directs a dedicated research team in her laboratory, that designs immunotherapeutic treatments and conducts bench to bedside translation.

Dr. Budde has authored a multitude of articles in leading scientific journals such as Nature Medicine, Lancet Oncology, Journal of Clinical Oncology, Blood, Journal of Hematology & Oncology, and Clinical Cancer Research. Her work has merited her invitations to speak at various national and international conferences. As the lead investigator for several cutting-edge translational research studies, Dr. Budde actively manages a diverse array of clinical trials. She is passionately committed to extending access to the latest medical advancements to her patients, ensuring they receive the most forward-thinking care available.

Visit the Elizabeth Budde Lab

Location

Education & Experience

Board Certifications

  • Medical Oncology
  • Internal Medicine

Degrees

  • 2001, M.D., Ph.D., Duke University of Medicine, Durham, NC
  • 1995, Bachelor of Medicine, Tongji Medical University Wuhan, Hubei, China

Fellowship

  • 2006-2009, University of Washington/ Fred Hutchinson Cancer Research Center, Seattle, WA

Residency

  • 2004-2006, Washington University School of Medicine, St. Louis, MO

Internship

  • 2003-2004, Intern, Internal Medicine, Washington University School of Medicine, St. Louis, MO

Professional Experience

  • 2022-present, Executive Medical Director, Enterprise Immune Effector Cell Program
  • 2020-present, Staff Physician and Associate Professor, Division of Lymphoma, Department of Hematologic Oncology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 2013-2020, Staff Physician and Assistant Professor, Department of Hematologic Oncology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 2009-2013, Acting Instructor, Department of Medicine, University of Washington, Seattle, Washington
  • 2009-2013, Attending Physician, Hematopoietic Cell Transplant Service, Seattle Cancer Care Alliance, Seattle, Washington
  • 2009-2013, Attending Physician, Lymphoma Clinic, Seattle Cancer Care Alliance, Seattle, Washington

Awards & Memberships

Awards

  • 2023-2027, Clinical Investigator, California Institute for Regenerative Medicine (CIRM)
  • 2017-2019, Clinical investigator (continuation award), Damon Runyon Cancer Research Foundation
  • 2014-2017, Clinical investigator, Damon Runyon Cancer Research Foundation
  • 2016, Greg Wiviott and Sharon & Robert Wiviott Seed grant, Stop Cancer Foundation
  • 2014-2017, Clinical investigator, Damon Runyon Cancer Research Foundation
  • 2014-2016, Tim Nesvig Lymphoma Research Foundation Fellow
  • 2013-2016, Awardee, Developmental Research Program, City of Hope Lymphoma SPORE (P50 CA 107399)
  • 2013-2016, Awardee, Career Enhancement Program, City of Hope Lymphoma SPORE
  • 2013-2015, Margaret E. Early Medical Trust Fund
  • 2013, Tower Cancer Foundation Research Grant
  • 2010-2012, Edson Immunotherapy Pilot Award
  • 2009-2012, Special Fellow in Clinical Research, Leukemia & Lymphoma Society
  • 2009, Participant, AACR/ASCO Workshop in Clinical Cancer Research
  • 2008, Participant, The 13th Annual NCCN Fellow Recognition Program
  • 2007, Participant, AACR Workshop on Molecular Biology in Clinical Oncology Workshop
  • 2005, Best Poster Presentation in Research Category for Medical Residents, American College of Physicians, Missouri Chapter Annual Meeting
  • 1999, Graduate Student Travel Award, B Cell Biology, Keystone International Meeting
  • 1997-2000, Research Assistantship, Duke University
  • 1995-1997, Graduate School Fellowship, Duke University
  • 1995, Graduation with Highest Honors, Tongji Medical University

Memberships

  • NCCN Guidelines for B Cell Lymphoma Panel
  • NCCN Guidelines for Management of Immunotherapy Related Toxicities Panel
  • AACI CAR T Working Group
  • Mantle Cell Lymphoma Consortium, Lymphoma Research Foundation
  • American Society of Hematology, Member
  • American Society of Clinical Oncology
  • Chinese American Faculty Association in Southern California (President, 2016)

Publications

  • Ong, S. Y., Pak, S., Mei, M., Wang, Y., Popplewell, L., Baird, J. H., Herrera, A. F., Shouse, G., Nikolaenko, L., Zain, J., Godfrey, J., Htut, M., Aribi, A., Spielberger, R., Mansour, J., Forman, S. J., Palmer, J., & Budde, L. E. (2023). Bendamustine Lymphodepletion Is a Well-tolerated Alternative to Fludarabine and Cyclophosphamide Lymphodepletion for Axicabtagene Ciloleucel Therapy for Aggressive B-cell Lymphoma. American Journal of Hematology, 10.1002/ajh.27069. Advance online publication.
  • Cao, Y., Marcucci, E. C., & Budde, L. E. (2023). Mosunetuzumab and Lymphoma: Latest Updates From 2022 ASH Annual Meeting. Journal of Hematology & Oncology, 16(1), 69.
  • Bartlett, N. L., Assouline, S., Giri, P., Schuster, S. J., Cheah, C. Y., Matasar, M., Gregory, G. P., Yoon, D. H., Shadman, M., Fay, K., Yoon, S. S., Panizo, C., Flinn, I., Johnston, A., Bosch, F., Sehn, L. H., Wei, M. C., Yin, S., To, I., Li, C. C., … Budde, L. E. (2023). Mosunetuzumab Monotherapy Is Active and Tolerable in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma. Blood Advances, 7(17), 4926–4935.
  • Ladbury, C., Dandapani, S., Hao, C., Fabros, M., Amini, A., Sampath, S., Glaser, S., Sokolov, K., Yeh, J., Baird, J. H., Kambhampati, S., Herrera, A., Mei, M., Nikolaenko, L., Shouse, G., & Budde, L. E. (2023). Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma. Cancers, 15(6), 1747.
  • Strati, P., Coleman, M., Champion, R., Ma, S., Patti, C., Levy, M. Y., Lossos, I. S., Geethakumari, P. R., Lam, S., Calvo, R., Higgins, K., & Budde, L. E. (2022). A Phase 2, Multicentre, Open-Label Trial (ACE-LY-003) of Acalabrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma. British Journal of Haematology, 199(1), 76–85.
  • Budde, L. E., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., Ku, M., Nastoupil, L., Cheah, C. Y., Wei, M. C., Yin, S., Li, C. C., Huang, H., Kwan, A., Penuel, E., & Bartlett, N. L. (2022). Safety and Efficacy of Mosunetuzumab, a Bispecific Antibody, in Patients With Relapsed or Refractory Follicular Lymphoma: A Single-Arm, Multicentre, Phase 2 Study. The Lancet. Oncology, 23(8), 1055–1065.
  • Budde, L. E., Assouline, S., Sehn, L. H., Schuster, S. J., Yoon, S. S., Yoon, D. H., Matasar, M. J., Bosch, F., Kim, W. S., Nastoupil, L. J., Flinn, I. W., Shadman, M., Diefenbach, C., O'Hear, C., Huang, H., Kwan, A., Li, C. C., Piccione, E. C., Wei, M. C., Yin, S., … Bartlett, N. L. (2022). Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology, 40(5), 481–491.
  • Dulan, S. O., Viers, K. L., Wagner, J. R., Clark, M. C., Chang, B., Gorospe, G. L., Londrc, A., Brown, A. S., Rosenthal, J., Smith, E. P., Forman, S. J., Snyder, D. S., & Budde, L. E. (2020). Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program. Biology of Blood and Marrow Transplantation: journal of the American Society for Blood and Marrow Transplantation, 26(8), 1386–1393.
  • Xue, T., & Budde, L. E. (2020). Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematology/Oncology Clinics of North America, 34(3), 575–587.
  • Budde, L. E., Wu, D., Martin, D. B., Philip, M., Shustov, A. R., Smith, S. D., Gooley, T. A., Chen, T. L., Libby, E. N., Chen, E. Y., Kojouri, K., Langerak, A., Roden, J. E., Press, O. W., & Gopal, A. K. (2018). Bendamustine With Rituximab, Etoposide and Carboplatin (T(R)EC) in Relapsed or Refractory Aggressive Lymphoma: A Prospective Multicentre Phase 1/2 Clinical Trial. British journal of haematology, 183(4), 601–607.
  • Kumar A, Casulo C, Advani RH, Budde E, Barr PM, Batlevi CL, Caron P, Constine LS, Dandapani SV, Drill E, Drullinsky P, Friedberg JW, Grieve C, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Joseph A, Khan N, Laraque L, Matasar MJ, Moskowitz AJ, Noy A, Palomba ML, Schöder H, Straus DJ, Vemuri S, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. J Clin Oncol. 2021 Jul 10;39(20):2257-2265. doi: 10.1200/JCO.21.00108. Epub 2021 Apr 28. PMID: 33909449.
  • Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012. PMID: 32135517.
  • Park SI, Shea TC, Olajide O, Reddy NM, Budde LE, Ghosh N, Deal AM, Noe JF, Ansell SM. ABVD Followed by BV Consolidation in Risk-Stratified Patients With Limited-Stage Hodgkin Lymphoma. Blood Adv. 2020 Jun 9;4(11):2548-2555. doi: 10.1182/bloodadvances.2020001871. PMID: 32516414; PMCID: PMC7284091.
  • Wang X, Huynh C, Urak R, Weng L, Walter M, Lim L, Vyas V, Chang WC, Aguilar B, Brito A, Sarkissian A, Bandara NA, Yang L, Wang J, Wu X, Zhang J, Priceman SJ, Qin H, Kwak LW, Budde LE, Thomas SH, Clark MC, Popplewell L, Siddiqi T, Brown CE, Forman SJ. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity Against Both Central Nervous System and Systemic Lymphoma. Cancer Immunol Res. 2020 Oct 22: canimm.0236.2020. doi: 10.1158/2326-6066.CIR-20-0236. Epub ahead of print. PMID: 33093217.
  • Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020 Sep 20;38(27):3095-3106. doi: 10.1200/JCO.19.02103. Epub 2020 Jul 15. PMID: 32667831; PMCID: PMC7499617.
  • Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. CD123 CAR T Cells for the Treatment of Myelodysplastic Syndrome. Exp Hematol. 2019
  • Budde LE, Wu D, Martin DB, Philip M, Shustov AR, Smith SD, Gooley TA, Chen TL, Libby EN, Chen EY, Kojouri K, Publications Langerak A, Roden JE, Press OW, Gopal AK. Bendamustine With Rituximab, Etoposide and Carboplatin (T(R)EC) in Relapsed or Refractory Aggressive Lymphoma: A Prospective Multicentre Phase 1/2 Clinical Trial. Br J Haematol. 2018 Nov;183(4):601-607. doi: 10.1111/bjh.15585. Epub 2018 Sep 14. PMID: 30596402; PMCID: PMC6314205.
  • Xue T, *Budde LE. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am. 2020 Jun;34(3):575-587. doi: 10.1016/j.hoc.2020.01.006. Epub 2020 Mar 27. PMID: 32336421. *corresponding author
  • Langerak A, Roden JE, Press OW, Gopal AK. Bendamustine With Rituximab, Etoposide and Carboplatin (T(R)EC) in Relapsed or Refractory Aggressive Lymphoma: A Prospective Multicentre Phase 1/2 Clinical Trial. Br J Haematol. 2018 Nov;183(4):601-607. doi: 10.1111/bjh.15585. Epub 2018 Sep 14. PMID: 30596402; PMCID: PMC6314205.
  • Dulan SO, Viers KL, Wagner JR, Clark M, Chang B, Gorospe GL, Londrc A, Brown AS, Rosenthal J, Smith EP, Forman SJ, Snyder DA, *Budde LE. Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program Biol Blood Marrow Transplant 2020;26(8):1386-1393. *corresponding author
  • Xue T, *Budde LE. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am. 2020 Jun;34(3):575-587. doi: 10.1016/j.hoc.2020.01.006. Epub 2020 Mar 27. PMID: 32336421. *corresponding author
  • Kumar A, Casulo C, Advani RH, Budde E, Barr PM, Batlevi CL, Caron P, Constine LS, Dandapani SV, Drill E, Drullinsky P, Friedberg JW, Grieve C, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Joseph A, Khan N, Laraque L, Matasar MJ, Moskowitz AJ, Noy A, Palomba ML, Schöder H, Straus DJ, Vemuri S, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. J Clin Oncol. 2021 Jul 10;39(20):2257-2265. doi: 10.1200/JCO.21.00108. Epub 2021 Apr 28. PMID: 33909449.
  • Wang X, Huynh C, Urak R, Weng L, Walter M, Lim L, Vyas V, Chang WC, Aguilar B, Brito A, Sarkissian A, Bandara NA, Yang L, Wang J, Wu X, Zhang J, Priceman SJ, Qin H, Kwak LW, Budde LE, Thomas SH, Clark MC, Popplewell L, Siddiqi T, Brown CE, Forman SJ. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity Against Both Central Nervous System and Systemic Lymphoma. Cancer Immunol Res. 2020 Oct 22: canimm.0236.2020. doi: 10.1158/2326-6066.CIR-20-0236. Epub ahead of print. PMID: 33093217.
  • Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020 Sep 20;38(27):3095-3106. doi: 10.1200/JCO.19.02103. Epub 2020 Jul 15. PMID: 32667831; PMCID: PMC7499617.
  • Park SI, Shea TC, Olajide O, Reddy NM, Budde LE, Ghosh N, Deal AM, Noe JF, Ansell SM. ABVD Followed by BV Consolidation in Risk-Stratified Patients With Limited-Stage Hodgkin Lymphoma. Blood Adv. 2020 Jun 9;4(11):2548-2555. doi: 10.1182/bloodadvances.2020001871. PMID: 32516414; PMCID: PMC7284091.
  • Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012. PMID: 32135517.
  • Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. HYPERLINK CD123 CAR T Cells for the Treatment of Myelodysplastic Syndrome. Exp Hematol. 2019 Jun;74:52-63.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Recommend this provider office
5.0
Provider explain in way you understand
5.0
Provider listen carefully to you
5.0
Show respect for what you say
4.9
Know important info medical history
4.9
Spend enough time with you
4.9
Rate provider 0-10
04/29/25
Detail and clear instruction on potential treatment options. Also mentions clearly which trial fit or not fit for me - Verified patient
04/28/25
I recommend COH to anyone who is in need of cancer care - Verified patient
04/26/25
Dr Budde was kind, attentive, and didn't rush through the appointment. - Verified patient
04/26/25
[...] Very happy with the service provided. - Verified patient
04/25/25
I am 84 yrs old and Dr Budde is the best Dr I have ever had - Verified patient